Role of dipeptidyl peptidase-4 (DPP4) on COVID-19 physiopathology

A Sebastián-Martín, BG Sánchez, JM Mora-Rodríguez… - Biomedicines, 2022 - mdpi.com
DPP4/CD26 is a single-pass transmembrane protein with multiple functions on glycemic
control, cell migration and proliferation, and the immune system, among others. It has …

Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis

S Schlesinger, A Lang, N Christodoulou, P Linnerz… - Diabetologia, 2023 - Springer
Aims/hypothesis To provide a systematic overview of the current body of evidence on high-
risk phenotypes of diabetes associated with COVID-19 severity and death. Methods This is …

Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis

NN Nguyen, DS Ho, HS Nguyen, DKN Ho, HY Li… - Metabolism, 2022 - Elsevier
Background Diabetes is an independent predictor of poor outcomes in patients with COVID-
19. We compared the effects of the preadmission use of antidiabetic medications on the in …

Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis

M Nassar, H Abosheaishaa, AK Singh… - Journal of …, 2023 - Wiley Online Library
Background Patients with diabetes are more likely to suffer COVID‐19 complications. Using
noninsulin antihyperglycemic medications (AGMs) during COVID‐19 infection has proved …

Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections

S Mani, A Kaur, K Jakhar, G Kumari, S Sonar… - International Journal of …, 2023 - Elsevier
Highly mutated SARS-CoV-2 is known aetiological factor for COVID-19. Here, we have
demonstrated that the receptor binding domain (RBD) of the spike protein can interact with …

Non-insulin novel antidiabetic drugs mechanisms in the pathogenesis of COVID-19

T Salmen, VA Pietroșel, BM Mihai, IC Bica… - Biomedicines, 2022 - mdpi.com
The present study aimed to analyse the published data and to realize an update about the
use and pathogenesis of the novel antidiabetic drugs, respectively, dipeptidyl peptidase-4 …

[HTML][HTML] Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control

N Narayanan, D Naik, J Sahoo… - World Journal of …, 2022 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality
and complications in patients with diabetes mellitus. Achieving good glycemic control is very …

Metformin use in relation to clinical outcomes and hyperinflammatory syndrome among COVID-19 patients with type 2 diabetes: a propensity score analysis of a …

CKH Wong, DTW Lui, AYC Lui, MCH Low… - Frontiers in …, 2022 - frontiersin.org
Aim This study was conducted in order to evaluate the association between metformin use
and clinical outcomes in type 2 diabetes mellitus (T2DM) patients hospitalized with …

The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies

ZH Song, QM Huang, SS Xu, JB Zhou… - Therapeutic Innovation & …, 2024 - Springer
Background Diabetes, a chronic disease worldwide, may be associated with a poorer
prognosis in patients with coronavirus disease 2019 (COVID-19). While some …

[PDF][PDF] Papel de la Dipeptidil Peptidasa-4 (DPP4) en la fisiopatología de la COVID-19.

AD Yuste, A Sebastián-Martín, BG Sánchez, A Bort… - dianas.web.uah.es
La DPP4/CD26 es una proteína transmembrana con múltiples funciones, entre las que se
encuentran la regulación de la glicemia, la migración y proliferación celular además de la …